Polish study probes ACE variant in Cavaliers with MMVD
Bottom line
Myxomatous mitral valve disease remains a defining health challenge for Cavalier King Charles Spaniels, and a new Polish study adds to the debate over how much one ACE gene variant can tell clinicians about risk. In Animals, researchers evaluated 105 Cavalier King Charles Spaniels from Poland for the rs850683722 ACE variant and assessed whether it influenced the course of MMVD, a disease already known to be especially common and often earlier-onset in this breed. Prior work has shown the variant is common in Cavaliers and is associated with lower ACE activity, but not necessarily with clear differences in age or disease severity. (eprints.gla.ac.uk)
Why it matters: For veterinary professionals, the practical takeaway is restraint. MMVD in Cavaliers is widely understood as a complex, polygenic disease, and broader reviews of the breed’s genetics have emphasized that no single marker has yet emerged as a stand-alone predictor of onset or progression. ACVIM guidance still centers staging and treatment on clinical findings, echocardiography, radiography, biomarkers, and signs of heart failure, not genotype alone. (ppm.sum.edu.pl)
What to watch: Whether this variant proves clinically useful will depend on larger, prospective studies that connect genotype to prognosis, treatment response, or breeding decisions across populations. (eprints.gla.ac.uk)
Key facts
- Study
- Polish study in Animals
- Breed
- Cavalier King Charles Spaniels
- Sample size
- 105 dogs
- Variant studied
- rs850683722 ACE variant
- Disease
- Myxomatous mitral valve disease (MMVD)
- Main question
- Whether the ACE variant influenced the course of MMVD
- Background
- MMVD is especially common, and often earlier onset, in Cavaliers
- Clinical takeaway
- No single marker has emerged as a stand-alone predictor of onset or progression
A new study in Animals examines whether the ACE gene variant rs850683722 is simply common in Polish Cavalier King Charles Spaniels, or whether it meaningfully changes the course of myxomatous mitral valve disease. That question matters because MMVD is the most common acquired cardiac disease in small-breed dogs and is especially prevalent, and often earlier in onset, in Cavaliers. (ppm.sum.edu.pl)
The backdrop here is years of work trying to untangle the breed’s heavy genetic burden. Reviews of the literature describe MMVD in Cavaliers as strongly heritable, but also complex and polygenic, with multiple candidate loci and pathways under study rather than a single causative mutation. Breeding programs have had mixed results, though Denmark’s more intensive screening approach, combining annual auscultation and echocardiography, has been associated with a lower prevalence of MMVD and later onset over time. (ppm.sum.edu.pl)
The ACE variant at the center of the new paper has been on researchers’ radar for several years. A 2018 study in Cavaliers with MMVD found a high prevalence of the ACE polymorphism and reported lower baseline ACE activity in variant-positive dogs, including in dogs with more advanced disease, but it did not find differences in mean age or median disease severity between dogs with and without the variant. The authors of that earlier work explicitly said the clinical significance, including any effect on the need for ACE inhibitors, required further study. (eprints.gla.ac.uk)
That uncertainty has persisted in the broader literature. Separate work has suggested the variant may affect renin-angiotensin-aldosterone system biology and the response profile to ACE-inhibitor therapy, while prevalence studies have found the variant is common in some breeds predisposed to heart disease. North Carolina State University’s veterinary hospital has described the test as offering insight into how effectively ACE inhibitors such as enalapril may work in an individual dog, but that framing is still better understood as hypothesis-generating than practice-changing. (pmc.ncbi.nlm.nih.gov)
Why it matters: For clinicians, this is less a story about a new actionable test than about the limits of single-variant interpretation in a common, multifactorial disease. In day-to-day practice, MMVD management still depends on careful staging, serial imaging, murmur assessment, clinical signs, and, when appropriate, biomarkers and standard therapies. For breeders and breed-health programs, the study may be useful as another data point on population genetics in Polish Cavaliers, but it does not appear to justify replacing phenotype-based screening with a single SNP result. That fits with the broader evidence base, which continues to support structured cardiac screening over simple genetic shortcuts. (ppm.sum.edu.pl)
Expert reaction specific to this Polish paper was limited in public sources at the time of review. Still, the surrounding literature points in a consistent direction: the ACE variant is biologically interesting, may influence ACE activity and possibly RAAS-related treatment dynamics, but has not yet been established as a reliable predictor of MMVD onset or progression on its own. That makes the new study most relevant as incremental evidence, not a pivot point for clinical protocols. (eprints.gla.ac.uk)
What to watch: The next step is validation in larger, ideally prospective cohorts that compare genotype with age of onset, progression speed, heart failure risk, and treatment response, especially in dogs receiving ACE inhibitors. If those studies show consistent outcome differences, the variant could become more relevant to screening or personalized cardiology. Until then, it’s best viewed as one piece of a much larger MMVD puzzle. (eprints.gla.ac.uk)